Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Harmony Biosciences Holdings (HRMY)

Harmony Biosciences names Peter Anastasiou COO; Troy Ignelzi joins board

Neutral Impact 3 of 5 leadership Written later

Harmony Biosciences appointed director Peter Anastasiou as Senior Executive Vice President and Chief Operating Officer effective April 2, 2026, and he resigned from the board. The board filled the vacancy with Troy Ignelzi, and director Antonio Gracias will not stand for re-election, with Geno J. Germano nominated to the board. The filing covers executive and board changes only and reports no financial results, so the effect on shareholders depends on how the new leadership executes the company's plans.

Key points

  • Peter Anastasiou named COO effective April 2, 2026, with a $600,000 base salary and a 55% target annual bonus
  • Anastasiou's option award has an aggregate grant date fair value of $3,700,000, vesting over four years
  • Troy Ignelzi appointed Class III director April 2, 2026; joins Audit and Compensation committees effective May 14, 2026
  • Antonio Gracias will not stand for re-election; Geno J. Germano nominated for election at the 2026 annual meeting

The filing

CompanyHarmony Biosciences Holdings (HRMY)
Form8-K, current report
Filed with the SECApr 2, 2026, 8:15 AM ET
Accession number0001104659-26-038888

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.